Eli Muchtar
Impact in
- Hematology top 1%
- Multiple Myeloma Research and Treatments
Papers in
-
- Amyloidosis: Diagnosis, Treatment, Outcomes 75
- Protein Degradation and Inhibitors 26
- Hematology 89
- Multiple Myeloma Research and Treatments 71
- Chronic Myeloid Leukemia Treatments 19
- Co-authors
- Morie A. Gertz (112 shared papers)Hila Magen (12 shared papers)Angela Dispenzieri (107 shared papers)Mical Paul (5 shared papers)Galia Kariv (3 shared papers)Leonard Leibovici (3 shared papers)Vered Shani (2 shared papers)Eyal Robenshtok (2 shared papers)
- Journals
- Blood (34 papers)Journal of Clinical Oncology (16 papers)Bone Marrow Transplantation (11 papers)American Journal of Hematology (10 papers)Blood Cancer Journal (8 papers)
- Partner nations
- United StatesIsraelSaudi Arabia
In The Last Decade
Eli Muchtar
166 papers receiving 2.9k citations
Eli Muchtar's Hit Papers
Peers
Comparison fields: 5 of 104
- Hematology 851
- Applied Microbiology and Biotechnology 119
- Genetics 638
- Nephrology 205
- Oncology 582
Countries citing papers authored by Eli Muchtar
This map shows the geographic impact of Eli Muchtar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eli Muchtar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eli Muchtar more than expected).
Fields of papers citing papers by Eli Muchtar
This network shows the impact of papers produced by Eli Muchtar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eli Muchtar. The network helps show where Eli Muchtar may publish in the future.
Co-authors
The 25 scholars most cited alongside Eli Muchtar, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 180 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Systematic Review and Meta-Analysis of the Efficacy of Appropriate Empiric Antibiotic Therapy for Sepsis Hit paper breakdown → | 2010 | 497 |
| 2 | 2017 | 210 | |
| 3 | 2020 | 170 | |
| 4 | 2016 | 117 | |
| 5 | 2019 | 81 | |
| 6 | 2018 | 70 | |
| 7 | 2018 | 63 | |
| 8 | 2016 | 55 | |
| 9 | 2009 | 53 | |
| 10 | 2016 | 51 | |
| 11 | 2013 | 48 | |
| 12 | 2016 | 45 | |
| 13 | 2017 | 44 | |
| 14 | 2019 | 43 | |
| 15 | 2020 | 40 | |
| 16 | 2018 | 40 | |
| 17 | 2016 | 39 | |
| 18 | 2016 | 39 | |
| 19 | 2020 | 36 | |
| 20 | 2019 | 36 |
About Eli Muchtar
Eli Muchtar is a scholar working on Molecular Biology, Hematology, Genetics, Oncology and Pathology and Forensic Medicine, having authored 180 papers that have together received 3.0k indexed citations. Recurring topics across this work include Amyloidosis: Diagnosis, Treatment, Outcomes (75 papers), Multiple Myeloma Research and Treatments (71 papers), Chronic Lymphocytic Leukemia Research (43 papers), Protein Degradation and Inhibitors (26 papers), Peptidase Inhibition and Analysis (20 papers), Chronic Myeloid Leukemia Treatments (19 papers), Lymphoma Diagnosis and Treatment (17 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (15 papers). The work is most often cited by research in Hematology (851 citations), Applied Microbiology and Biotechnology (119 citations), Genetics (638 citations), Nephrology (205 citations) and Oncology (582 citations). Eli Muchtar has collaborated with scholars based in United States, Israel and Saudi Arabia. Frequent co-authors include Morie A. Gertz, Hila Magen, Angela Dispenzieri, Mical Paul, Galia Kariv, Leonard Leibovici, Vered Shani, Eyal Robenshtok, Francis K. Buadi and Shaji Kumar. Their work appears in journals such as Blood, Journal of Clinical Oncology, Bone Marrow Transplantation, American Journal of Hematology and Blood Cancer Journal.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.